EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Initial Experience with Transcatheter Tricuspid Valve Repair in Patients with Cardiac Amyloidosis

Isabel A Hoerbrand iD, Martin J Volz, Fabian Aus dem Siepen, Matthias Aurich, Philipp Schlegel, Nicolas A Geis, Ute Hegenbart, Mathias H Konstandin, Norbert Frey, Philip W Raake

ESC Heart Failure · 01.04.2023 · 10 (2) · 1003-1012

DOI: 10.1002/ehf2.14262 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ESC Heart Failure, online erschienen am 13.12.2022. Verfasst von Isabel A Hoerbrand und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine III, Division of Cardiology, University Hospital Heidelberg, Ruprecht-Karl University Heidelberg, 69120, Heidelberg, …. Hauptthemen laut MEDLINE: Amyloidosis, Cardiac Catheterization, Tricuspid Valve, Tricuspid Valve Insufficiency. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Wildtype transthyretin amyloid cardiomyopathy is an under-recognized cause of heart failure in elderly patients. Transcatheter tricuspid valve repair is a newly emerging therapeutic option for severe tricuspid regurgitation (TR). We present first insights into safety and possible benefits of this procedure in patients with cardiac amyloidosis. Methods and results Eight patients with cardiac non-hereditary (wildtype) transthyretin (ATTRwt) amyloidosis and severe to torrential TR, undergoing successful transcatheter tricuspid valve repair, were included in the analysis and compared to a control group of 21 patients without cardiac amyloidosis. All patients presented with an advanced stage of amyloid cardiomyopathy. Primary endpoint was reduction in TR at 3 months follow-up. Secondary endpoints were feasibility, safety, hospitalization or death, clinical improvement, cardiac biomarkers, and structural and functional right heart parameter obtained by echocardiography. Transcatheter tricuspid valve repair resulted in a significant reduction of TR (IV to II, P = 0.008) in all eight patients with cardiac amyloidosis (100%). Device success (amyloidosis 75% vs. control group 86%, P = 0.597) and overall probability of hospitalization or death (amyloidosis 13% vs. control group 25%, P = 0.646) were similar compared with those in the control group at 3 months follow-up. Transcatheter tricuspid valve repair led to an improvement of New York Heart Association functional class (P = 0.031) and 6 min walking distance (from 313 ± 118 to 337 ± 106, P = 0.012). TR reduction in amyloidosis patients was less extensive compared with that in control group (TR-reduction 1.6 ± 0.3, P = 0.008 vs. control group 2.3 ± 0.3, P < 0.0001). Furthermore, these patients showed no significant improvement of structural right heart parameters.

Conclusions

Transcatheter tricuspid valve repair is a safe and feasible new treatment option in patients with amyloid cardiomyopathy and has the potential to improve TR-grade and clinical status. However, the benefit appears to be less pronounced compared with patients without cardiac amyloidosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AmyloidosisCardiac CatheterizationTricuspid ValveTricuspid Valve InsufficiencyAgedHumansPrealbuminTreatment Outcome

Stichwörter der Autor:innen

Amyloid cardiomyopathyCardiac amyloidosisTranscatheter tricuspid valve repairTricuspid regurgitation

Substanzen

Prealbumin

Autor:innen und Institutionen

  • Department of Internal Medicine III, Division of Cardiology, University Hospital Heidelberg, Ruprecht-Karl University Heidelberg, 69120, Heidelberg, Germany.
  • Department of Internal Medicine V, Division of Hematology and Oncology, Amyloidosis Center, University Hospital Heidelberg, Ruprecht-Karl University Heidelberg, Heidelberg, Germany.
  • DZHK (German Center for Cardiovascular Research), partner site Heidelberg/Mannheim, Heidelberg, Germany.

ORCID-Profile: Isabel A Hoerbrand

Zitieren

APA

Hoerbrand, I. A., Volz, M. J., Aus dem Siepen, F., Aurich, M., Schlegel, P., Geis, N. A., Hegenbart, U., Konstandin, M. H., Frey, N., & Raake, P. W. (2023). Initial Experience with Transcatheter Tricuspid Valve Repair in Patients with Cardiac Amyloidosis. ESC Heart Failure, 10(2), 1003-1012. https://doi.org/10.1002/ehf2.14262

Vancouver

Hoerbrand IA, Volz MJ, Aus dem Siepen F, Aurich M, Schlegel P, Geis NA, et al. Initial Experience with Transcatheter Tricuspid Valve Repair in Patients with Cardiac Amyloidosis. ESC Heart Failure. 2023;10(2):1003-1012. doi:10.1002/ehf2.14262

BibTeX
@article{Hoerbrand2023,
  author = {Hoerbrand, Isabel A and Volz, Martin J and Aus dem Siepen, Fabian and Aurich, Matthias and Schlegel, Philipp and Geis, Nicolas A and Hegenbart, Ute and Konstandin, Mathias H and Frey, Norbert and Raake, Philip W},
  title = {Initial Experience with Transcatheter Tricuspid Valve Repair in Patients with Cardiac Amyloidosis},
  journal = {ESC Heart Failure},
  year = {2023},
  volume = {10},
  number = {2},
  pages = {1003--1012},
  doi = {10.1002/ehf2.14262}
}
Kostenlos starten →